179 related articles for article (PubMed ID: 11363186)
1. Merck protease inhibitor: more news from Retroviruses Conference.
James JS
AIDS Treat News; 1996 Feb; (no 241):1-3. PubMed ID: 11363186
[TBL] [Abstract][Full Text] [Related]
2. Protease inhibitors shine in triple combinations.
AIDS Alert; 1996 Mar; 11(3):31-2. PubMed ID: 11363243
[TBL] [Abstract][Full Text] [Related]
3. Major protease inhibitor triple combination trial begins soon: CD4 under 200, AZT experienced, 3TC naive.
James JS
AIDS Treat News; 1995 Dec; (no 237):3. PubMed ID: 11363075
[TBL] [Abstract][Full Text] [Related]
4. Update on HIV protease inhibitors.
Vella S
AIDS Clin Care; 1995 Oct; 7(10):79-82, 88. PubMed ID: 11362832
[TBL] [Abstract][Full Text] [Related]
5. Another option for less than 50 T4 cells.
Treat Rev; 1995; (no 19):3. PubMed ID: 11362755
[TBL] [Abstract][Full Text] [Related]
6. Protease inhibitors and prevention of cross resistance.
Levin J
AIDS Treat News; 1995 Oct; (no 232):1-3. PubMed ID: 11362875
[TBL] [Abstract][Full Text] [Related]
7. A Lisbon traviata. Are clinicians ready to sing addio to monotherapy and libiamo to combinations?
Mascolini M
J Int Assoc Physicians AIDS Care; 1995 Sep; 1(8):10-20, 22. PubMed ID: 11362792
[TBL] [Abstract][Full Text] [Related]
8. Nipping HIV in the bud.
Smart T
GMHC Treat Issues; 1996 Aug; 10(8):3-6. PubMed ID: 11363719
[TBL] [Abstract][Full Text] [Related]
9. AZT studies reinforce benefits of combination.
AIDS Alert; 1995 Jan; 10(1):11-2. PubMed ID: 11362167
[TBL] [Abstract][Full Text] [Related]
10. Back to the nukes.
Smart T
GMHC Treat Issues; 1996 Feb; 10(2):6-7. PubMed ID: 11363383
[TBL] [Abstract][Full Text] [Related]
11. Conference looks at HIV drug resistance.
Chang HE
GMHC Treat Issues; 1995 Sep; 9(9):6-8. PubMed ID: 11362910
[TBL] [Abstract][Full Text] [Related]
12. Treatment briefs.
Gilden D
GMHC Treat Issues; 1995 Apr; 9(4):6. PubMed ID: 11362367
[TBL] [Abstract][Full Text] [Related]
13. New protease inhibitor studies.
Treat Rev; 1995 May; (no 18):2. PubMed ID: 11362591
[TBL] [Abstract][Full Text] [Related]
14. [Observational study on the efficacy of the application of two classical regimens of triple antiretroviral therapy].
Eiros Bouza JM; Ortega Lafont M; Ortiz de Lejarazu R; Bachiller Luque P; de Luis Román DA
An Med Interna; 2003 May; 20(5):239-42. PubMed ID: 12831297
[TBL] [Abstract][Full Text] [Related]
15. AIDS therapy with two, three or four agent combinations, applied in short sequences, differing from each other by drug rotation. I. First of two parts: a phase I trial equivalent, concerning five virostatics: AZT, ddI, ddC, acriflavine and an ellipticine analogue.
Mathé G; Pontiggia P; Orbach-Arbouys S; Triana K; Ambetima N; Morette C; Hallard M; Blanquet D
Biomed Pharmacother; 1996; 50(5):220-7. PubMed ID: 8949403
[TBL] [Abstract][Full Text] [Related]
16. Potent new AIDS drugs underscore promise of combination therapy.
AIDS Alert; 1996 Jan; 11(1):1-4. PubMed ID: 11363225
[TBL] [Abstract][Full Text] [Related]
17. New double vs. triple antiviral combination study, CD4 200-500, no prior treatment.
James JS
AIDS Treat News; 1995 Dec; (no 236):7. PubMed ID: 11363052
[TBL] [Abstract][Full Text] [Related]
18. New drugs for HIV infection.
Med Lett Drugs Ther; 1996 Apr; 38(972):35-7. PubMed ID: 8606677
[TBL] [Abstract][Full Text] [Related]
19. Eradication of HIV: the cutting edge of clinical trial design.
Crit Path AIDS Proj; 1996; (No 31):16-7. PubMed ID: 11363825
[TBL] [Abstract][Full Text] [Related]
20. ddI and d4T plus protease inhibitors.
GMHC Treat Issues; 1996 Nov; 10(11):8-9. PubMed ID: 11364012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
